Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 24 2020 - 4:51PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of the
Securities
Exchange Act of 1934
For
the month of November 2020
Commission
File Number: 001-36581
Vascular
Biogenics Ltd.
(Translation
of registrant’s name into English)
8
HaSatat St.,
Modi’in,
Israel
7178106
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F [X]
|
|
Form
40-F [ ]
|
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
_______
EXPLANATORY
NOTE
As
previously disclosed, on November 24, 2020, Vascular Biogenics Ltd. (the “Company”) convened an extraordinary general
meeting of shareholders (the “Meeting”) at 4.00 p.m. (Israel time) at the Company’s offices at 8 HaSatat St.
Modi’in, Israel.
At
the Meeting, following establishment of a quorum, the Company’s shareholders voted on one proposal which is summarized below
and described in more detail in the Company’s (i) Notice of Extraordinary General Meeting of Shareholders of Vascular Biogenics
Ltd. and (ii) Proxy Statement and Proxy Card for use in connection with the Meeting that were attached as Exhibits 99.1 and 99.2
to a Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission on October
19, 2020.
Proposal:
To elect Mr. Marc Kozin as a member of the Board of Directors of the Company, to serve until the next annual general meeting of
shareholders of the Company or until his successor is duly appointed and qualified, or until his earlier resignation or removal
and to approve the compensation terms and equity grant as fully described in the proxy statement.
Based
on voting results at the Meeting, the majority requirements for the proposals under the Israeli Companies Law 5759-1999 and the
Articles of Association of the Company, the above proposal was properly approved at the Meeting.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
VASCULAR
BIOGENICS LTD.
|
|
|
Date:
November 24, 2020
|
By:
|
/s/
Dror Harats
|
|
Name:
|
Dror
Harats
|
|
Title:
|
Chief
Executive Officer
|
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024